Literature DB >> 21598308

Bisphosphonate treatment delays stress fracture remodeling in the rat ulna.

L J Kidd1, N R Cowling, A C K Wu, W L Kelly, M R Forwood.   

Abstract

Because bisphosphonates (BPs) are potent inhibitors of bone resorption, we hypothesized that they would retard direct remodeling of stress fractures. The aim of this study was to determine the effect of risedronate on direct remodeling and woven bone callus formation following stress fracture formation in the rat ulna. In 135 adult female Wistar rats, cyclic loading of the ulna created stress fractures. Rats were treated daily with oral saline, or risedronate at 0.1 or 1.0 mg/kg. From each bone, histomorphometry was performed on sections stained with toluidine blue at a standard level along the fracture. The high dose of risedronate caused a significant decrease in the percentage of repaired stress fracture and bone resorption along the stress fracture line at 6 and 10 weeks after loading (p < 0.05). At this dose, intracortical resorption was significantly reduced at 10 weeks after loading and intracortical new bone area was significantly reduced at 6 and 10 weeks. Woven bone formation and consolidation phases of stress fracture repair were not affected by low or high doses of risedronate. In conclusion, high dose bisphosphonate treatment impaired healing of a large stress fracture line by reducing the volume of bone resorbed and replaced during remodeling. We also confirmed that periosteal callus formation was not adversely affected by risedronate treatment.
Copyright © 2011 Orthopaedic Research Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21598308     DOI: 10.1002/jor.21464

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  18 in total

Review 1.  Atypical femoral fractures: epidemiology, etiology, and patient management.

Authors:  Eve Donnelly; Anas Saleh; Aasis Unnanuntana; Joseph M Lane
Journal:  Curr Opin Support Palliat Care       Date:  2012-09       Impact factor: 2.302

2.  Undisturbed local bone formation capacity in patients with atypical femoral fractures: a case series.

Authors:  H P Bögl; P Aspenberg; J Schilcher
Journal:  Osteoporos Int       Date:  2017-05-04       Impact factor: 4.507

3.  Resting and injury-induced inflamed periosteum contain multiple macrophage subsets that are located at sites of bone growth and regeneration.

Authors:  Kylie Anne Alexander; Liza-Jane Raggatt; Susan Millard; Lena Batoon; Andy Chiu-Ku Wu; Ming-Kang Chang; David Arthur Hume; Allison Robyn Pettit
Journal:  Immunol Cell Biol       Date:  2016-11-15       Impact factor: 5.126

Review 4.  Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw.

Authors:  J Compston
Journal:  Osteoporos Int       Date:  2011-10-14       Impact factor: 4.507

Review 5.  Bisphosphonates and their influence on fracture healing: a systematic review.

Authors:  H Molvik; W Khan
Journal:  Osteoporos Int       Date:  2015-01-09       Impact factor: 4.507

Review 6.  Rib Fractures in Professional Baseball Pitchers: Mechanics, Epidemiology, and Management.

Authors:  Sean Schowalter; Bryan Le; James Creps; Kelly C McInnis
Journal:  Open Access J Sports Med       Date:  2022-10-10

Review 7.  Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.

Authors:  Beatrice J Edwards; Andrew D Bunta; Joseph Lane; Clarita Odvina; D Sudhaker Rao; Dennis W Raisch; June M McKoy; Imran Omar; Steven M Belknap; Vishvas Garg; Allison J Hahr; Athena T Samaras; Matthew J Fisher; Dennis P West; Craig B Langman; Paula H Stern
Journal:  J Bone Joint Surg Am       Date:  2013-02-20       Impact factor: 5.284

Review 8.  How do bisphosphonates affect fracture healing?

Authors:  Stephen L Kates; Cheryl L Ackert-Bicknell
Journal:  Injury       Date:  2016-01       Impact factor: 2.586

9.  Chemical IN04 Inhibits the Kinase Domain not the ROC Domain of LRRK1: Results from Homology Modeling and Molecular Docking.

Authors:  Zhenhang Chen; Weirong Xing; Li Fan
Journal:  Med Chem       Date:  2021       Impact factor: 2.745

10.  Targeted disruption of leucine-rich repeat kinase 1 but not leucine-rich repeat kinase 2 in mice causes severe osteopetrosis.

Authors:  Weirong Xing; Jeff Liu; Shaohong Cheng; Peter Vogel; Subburaman Mohan; Robert Brommage
Journal:  J Bone Miner Res       Date:  2013-09       Impact factor: 6.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.